Biogen’s Higher-Dose Spinraza Shows Better Efficacy, But Franchise Stands To Lose Market Share

The higher-dose version of Biogen’s SMA drug showed better efficacy than the approved 12mg dose, which could help it maintain a market foothold, but competitors are likely to overtake it.